- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner | 555 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric... ► Artikel lesen | |
| 23.04. | Protagenic ernennt Bill Nichols zum Präsidenten, Finanzvorstand tritt zurück | 4 | Investing.com Deutsch | ||
| 23.04. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 | 288 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related... ► Artikel lesen | |
| 07.04. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | Protagenic settles Phytanix separation, cuts liabilities by $6.3M | 2 | Investing.com | ||
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 | 249 | ACCESS Newswire | Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW... ► Artikel lesen | |
| 10.03. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market | 230 | ACCESS Newswire | Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics... ► Artikel lesen | |
| 09.03. | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.03. | Protagenic Therapeutics beruft William Nichols Jr. zum President | 2 | Investing.com Deutsch | ||
| 03.03. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 18.02. | Protagenic Therapeutics, Inc.\new - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| 23.01. | NSE - Protagenic Therapeutics, Inc.\new - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 05.01. | Protagenic Therapeutics wechselt nach NASDAQ-Delisting in den OTC-Handel | 6 | Investing.com Deutsch | ||
| 05.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 09.12.25 | Protagenic Therapeutics, Inc.: Results from Phase 1 Multiple-Dose Study of PT00114 | 443 | ACCESS Newswire | Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic... ► Artikel lesen | |
| 27.11.25 | Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | 631 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| 13.11.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 398 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and... ► Artikel lesen | |
| 22.08.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance | 611 | ACCESS Newswire | Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing novel... ► Artikel lesen | |
| 21.08.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders | 426 | ACCESS Newswire | Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,021 | 0,00 % | Medigene AG: Widerruf der Zulassung zum regulierten Markt | Beschluss
Medigene AG, Planegg
Widerruf der Zulassung zum regulierten Markt
Auf Antrag der Gesellschaft wird die Zulassung der auf den Namen lautenden Stammaktien (ISIN: DE000A40ESG2) zum regulierten... ► Artikel lesen | |
| VALNEVA | 2,265 | -0,04 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| BIOFRONTERA | 2,330 | +0,43 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des ersten Quartals 2026 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN QUARTALS 2026
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA BERICHTET ÜBER... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 11,440 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,300 | -0,30 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | +5,80 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 7,590 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,540 | -1,91 % | Microbot Medical Inc.: Microbot Medical Announces First Health System in Pennsylvania to Adopt the LIBERTY Endovascular Robotic System | ||
| RECURSION PHARMACEUTICALS | 3,520 | 0,00 % | Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech outlines pancreatic cancer trial milestones | ||
| OCULAR THERAPEUTIX | 8,800 | +1,73 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen PROTAGENIC THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,56 % bei einem Aktienkurs von 1,588 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.